Table 1.
Baseline characteristics (N = 142)a
| Characteristic | Value |
|---|---|
| Age, mean (SD), y | 65 (10) |
| Weight, mean (SD), kg | 86 (20) |
| Sex, male, no. (%) | 76 (54) |
| Race/ethnicity, no. (%) | |
| White | 133 (94) |
| Black | 5 (4) |
| Hispanic | 4 (3) |
| Comorbidities, no. (%) | |
| Coronary heart diseaseb | 40 (28) |
| Hypertensionc | 70 (49) |
| Diabetes mellitus type 2 | 25 (18) |
| Statin,no. (%) | |
| Simvastatind | 60 (42) |
| Atorvastatin | 29 (20) |
| Rosuvastatin | 23 (16) |
| Pravastatin | 19 (13) |
| Lovastatin | 6 (4) |
| Red yeast rice | 4 (3) |
| Pitavastatin | 1 (1) |
| Normalized statin dose, mean (SD), mge | 17 (18) |
| Normalized statin dose, mean (SD), mg/kg body weighte | 0.2 (0.2) |
| Duration of statin therapy, mean (SD), y | 6.8 (5.7) |
a
Some percentages do not total to 100 because of rounding.
b
All patients with coronary heart disease had normal ejection fraction and normal left ventricular end-diastolic pressure before statin treatment.
c
Hypertension without evidence of left ventricular hypertrophy.
d
Includes patients receiving the ezetimibe/simvastatin combination drug (n=10).
e
Dose normalized to atorvastatin potency; excludes red yeast rice.
SD = standard deviation.